Volpara bid underwhelming but hard to beat: Bell Potter

Volpara bid underwhelming but hard to beat: Bell Potter
Volpara has developed a breast cancer detection system. (Image: NZME)
Pattrick Smellie
The bid by South Korean firm Lunit to take over fast-growing Wellington medical AI provider Volpara Technologies at A$1.15 (NZ$1.124) a share is no more than “good enough”, but is unlikely to be beaten, says Sydney broking house Bell Potter.Pitched at a 47.4% premium to Australian securties exchange-listed (ASX) Volpara’s closing price on Dec 13, the offer values the company, which is on the cusp of profitability after more than seven years as a publicly listed company, at a “mere US$193 million [NZ$311m]”.How...

More Markets

Auckland Airport dominates volumes; NZX dips 0.61%
Markets Market Close

Auckland Airport dominates volumes; NZX dips 0.61%

The S&P/ASX 200 has recovered from the US's so-called "Liberation Day".

Pacific Edge upbeat about latest move for new test
Markets

Pacific Edge upbeat about latest move for new test

The median price for Cxbladder Triage Plus is US$1,018.44.

Pacific Edge reviews US pricing for new Cxbladder test
Markets

Pacific Edge reviews US pricing for new Cxbladder test

Cxbladder Triage Plus is a ‘next-generation’ Cxbladder test.